
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is supported by a lead asset, vidofludimus calcium, that has Phase 2 evidence of relapse reduction, MRI lesion suppression, and durable disability control, while also showing a favorable safety and tolerability profile across 3500+ patients with no clear hepatotoxicity or serious infection signal. Its opportunity is amplified by a large MS market over $20B, meaningful unmet need in progression despite existing therapies, and a differentiated dual mechanism that may address both inflammation and neuroprotection, while EN SURE-1 and ENSURE-2 enrolled 1,121 and 1,100 patients and are expected to report topline by the end of 2026. Financially, the company also benefits from about $200MM gross PIPE proceeds in February 2026 and patent coverage that may extend to 2041-2045, which together improve runway visibility and protect long-term commercialization potential.
Bears say
Immunic is exposed to substantial clinical and regulatory risk because its lead asset, vidofludimus calcium, could fail to show sufficient efficacy or could face a safety signal that disrupts development or adoption. Even with 3500+ patients dosed and no observed increase in hepatotoxicity or serious infections to date, the bear-case analysis still implies weak commercial penetration, with modeled market share as low as 0.4% to 0.5% and valuation outcomes below $0.4B. The company also faces dilution risk from warrant exercise, possible manufacturing or shipment issues, and likely additional funding needs over a 3.5-4 year Phase 3 timeline, while competition from approved and generic DMTs limits sales upside.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Immunic Inc (IMUX) Forecast
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares